Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.50 |
| ▸ | PDE4A | P27815 | 8/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2958828 | 0.94 | RECQL (0.60) | RECQLPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL8846224 | 0.90 | RECQL (0.55) | RECQLHDAC1HDAC2PDE4BPDE4A | |
| SCHEMBL13111720 | 0.86 | RECQL (0.61) | RECQLHDAC1HDAC2PDE4BPDE4A | |
| SCHEMBL14244189 | 0.84 | RECQL (0.60) | RECQLHDAC1HDAC2PDE4BPDE4A | |
| SCHEMBL3456387 | 0.84 | RECQL (0.60) | RECQLHDAC1HDAC2PDE4BPDE4A | |
| SCHEMBL13986189 | 0.84 | RECQL (0.60) | RECQLHDAC1HDAC2PDE4BPDE4A | |
| SCHEMBL28130686 | 0.84 | RECQL (0.64) | RECQLHDAC1HDAC2PDE4BPDE4A | |
| SCHEMBL7783172 | 0.83 | RECQL (0.59) | RECQLHDAC1HDAC2PDE4BPDE4A | |
| SCHEMBL6366618 | 0.82 | RECQL (0.58) | RECQLHDAC1HDAC2PDE4BPDE4A | |
| SCHEMBL31661693 | 0.82 | RECQL (0.58) | RECQLHDAC1HDAC2PDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205593-B1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2016-01-13 | — | — | EP | disclosed |
| EP-2416777-B1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI SA (FR) | 2014-11-12 | — | — | EP | disclosed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8748441-B2 | Therapeutic uses of quinazolinedione derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| EP-2411009-B1 | Therapeutic uses of quinazolinedione derivatives | SANOFI SA (FR) | 2013-03-20 | — | — | EP | disclosed |
| US-8242126-B2 | Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2012-08-14 | — | — | US | disclosed |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-07-19 | — | — | US | disclosed |
| CN-102458409-A | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI AVENTIS | 2012-05-16 | — | — | CN | disclosed |
| CN-102448461-A | Therapeutic uses of quinazolinedione derivatives | SANOFI AVENTIS | 2012-05-09 | — | — | CN | disclosed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| WO-2010109148-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| EP-2205593-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| WO-2009077680-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | WO | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | RECQL 3524/4885ACHE 230/4885HDAC1 1625/4885 |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | RECQL 3524/4885ACHE 230/4885HDAC1 1625/4885 |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | FABP3, SLC5A1, SLC5A2 | RECQL 404/4885ACHE 1405/4885HDAC1 329/4885 |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SLC5A2, SLC5A1, PPARD | RECQL 662/4885ACHE 189/4885HDAC1 469/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | RECQL 3524/4885ACHE 230/4885HDAC1 1625/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | RECQL 3524/4885ACHE 230/4885HDAC1 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.